Diuretics, arrhythmias and silent myocardial ischaemia in hypertensive patients

L Storstein1

  • 1International Cardiological Institute for Therapeutic Research, University of Oslo, Norway.

European Heart Journal
|December 1, 1992
PubMed

Insights

High blood pressure significantly elevates sudden death risk. Ventricular arrhythmias and silent ischemia are key independent predictors of cardiac events in hypertensive patients.

Area of Science:

  • Cardiology
  • Hypertension Research

Background:

  • Hypertension increases sudden death risk, particularly with high systolic blood pressure (>155 mmHg).
  • Ventricular premature contractions and ventricular arrhythmias are more prevalent in hypertensive individuals, especially those with left ventricular hypertrophy.
  • Silent myocardial ischemia is an independent predictor of cardiac events and potentially sudden death in hypertensive patients.

Purpose of the Study:

  • To investigate the risk factors for sudden death in patients with high blood pressure.
  • To explore the relationship between ventricular arrhythmias, silent ischemia, and cardiac events in hypertension.

Main Methods:

  • Analysis of risk factors including systolic blood pressure, ventricular arrhythmias, and silent ischemia.
  • Comparison of sudden death risk between different blood pressure quintiles.
  • Evaluation of the association between ventricular tachycardia, silent ischemia, and cardiac events.

Main Results:

  • Patients in the highest systolic blood pressure quintile (>155 mmHg) have a 3.2 times greater risk of sudden death.
  • Ventricular arrhythmias and silent ischemia are identified as important and independent risk factors for cardiac events in hypertensive patients.
  • Ninety-two percent of patients with both ventricular tachycardia and silent myocardial ischemia experienced morbid cardiac events, versus 37% without either condition.

Conclusions:

  • Ventricular arrhythmias and silent ischemia are significant independent predictors of cardiac events in hypertensive individuals.
  • While the causal link between arrhythmias and sudden death remains uncertain, their presence alongside silent ischemia indicates a high risk for adverse cardiac events.

Related Concept Videos

Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various tubules...
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...